Guckelberger Olaf, Sun Xiao Feng, Sévigny Jean, Imai Masato, Kaczmarek Elzbieta, Enjyoji Keiichi, Kruskal Jonathan B, Robson Simon C
Department of Visceral- and Transplantation-Surgery, Charité Campus Virchow-Clinic, Humboldt University, Berlin, Germany.
Thromb Haemost. 2004 Mar;91(3):576-86. doi: 10.1160/TH03-06-0373.
CD39 (ecto-nucleoside triphosphate diphosphohydrolase-1; E-NTPDase-1), is highly expressed on quiescent vascular endothelial cells and efficiently hydrolyzes extracellular ATP and ADP to AMP and ultimately adenosine. This action blocks extracellular nucleotide-dependent platelet aggregation and abrogates endothelial cell activation. However, CD39 enzymatic activity is rapidly lost following exposure to oxidant stress. Modulation of extracellular nucleotide levels may therefore play an important role in the pathogenesis of vascular injury. Acute ischemic injury of the bowel is a serious medical condition characterized by high mortality rates with limited therapeutic options. Here we evaluate the effects of cd39-deletion in mutant mice and the use of supplemental NTPDase or adenosine in influencing the outcomes of intestinal ischemia-reperfusion. Wild-type, cd39-null, or hemizygous cd39-deficient mice were subjected to intestinal ischemia. In selected animals, 0.2 U/g apyrase (soluble NTPDase) was administered prior to re-establishment of blood-flow. In parallel experiments adenosine/amrinone was infused over 60 min during reperfusion periods. Survival rates were determined, serum and tissue samples were taken. Intravital videomicroscopy and studies of vascular permeability were used to study platelet-endothelial cell interactions and determine capillary leakage. In wild-type animals, ischemia reperfusion injury resulted in 60% mortality within 48 hours. In mutant mice null or deficient for cd39, ischemia reperfusion-related death occurred in 80% of animals. Apyrase supplementation protected all wild-type animals from death due to intestinal ischemia but did not fully protect cd39-null and cd39-hemizygote mice. Adenosine/amrinone treatment failed to improve survival figures. In wild type mice, platelet adherence to postcapillary venules was significantly decreased and vascular integrity was well preserved following apyrase administration. In cd39-null mice, ischemia-reperfusion induced marked albumin leakage indicative of heightened vascular permaeability when compared to wild-type animals (p=0.04). Treatment with NTPDase or adenosine supplementation abrogated the increased vascular permeability in ischemic jejunal specimens of both wild-type mice and cd39-null. CD39 activity modulates platelet activation and vascular leak during intestinal ischemia reperfusion injury in vivo. The potential of NTPDases to maintain vascular integrity suggests potential pharmacological benefit of these agents in mesenteric ischemic injury.
CD39(胞外核苷三磷酸二磷酸水解酶-1;E-NTPDase-1)在静止的血管内皮细胞上高度表达,能有效地将细胞外ATP和ADP水解为AMP,最终生成腺苷。这一作用可阻断细胞外核苷酸依赖性血小板聚集,并消除内皮细胞活化。然而,暴露于氧化应激后,CD39的酶活性会迅速丧失。因此,细胞外核苷酸水平的调节可能在血管损伤的发病机制中起重要作用。肠道急性缺血性损伤是一种严重的病症,死亡率高且治疗选择有限。在此,我们评估了突变小鼠中CD39缺失的影响,以及补充NTPDase或腺苷对肠道缺血再灌注结局的影响。将野生型、CD39基因敲除或半合子CD39缺陷小鼠进行肠道缺血处理。在选定的动物中,在恢复血流前给予0.2 U/g的腺苷三磷酸双磷酸酶(可溶性NTPDase)。在平行实验中,在再灌注期间60分钟内输注腺苷/氨力农。测定存活率,采集血清和组织样本。利用活体视频显微镜和血管通透性研究来研究血小板-内皮细胞相互作用并确定毛细血管渗漏。在野生型动物中,缺血再灌注损伤导致48小时内死亡率达60%。在CD39基因敲除或缺陷的突变小鼠中,80%的动物发生缺血再灌注相关死亡。补充腺苷三磷酸双磷酸酶可保护所有野生型动物免于因肠道缺血而死亡,但不能完全保护CD39基因敲除和CD39半合子小鼠。腺苷/氨力农治疗未能提高存活率。在野生型小鼠中,给予腺苷三磷酸双磷酸酶后,血小板对毛细血管后微静脉的黏附显著减少,血管完整性得到良好保存。在CD39基因敲除小鼠中,与野生型动物相比,缺血再灌注诱导明显的白蛋白渗漏,表明血管通透性增加(p=0.04)。用NTPDase治疗或补充腺苷可消除野生型小鼠和CD39基因敲除小鼠缺血空肠标本中增加的血管通透性。CD39活性在体内肠道缺血再灌注损伤期间调节血小板活化和血管渗漏。NTPDases维持血管完整性的潜力表明这些药物在肠系膜缺血性损伤中具有潜在的药理学益处。